New drug ML-004 moves to safety testing in autism patients
Disease control
Ongoing
This study is testing the safety of an experimental drug called ML-004 in 120 adolescents and adults with autism spectrum disorder who have already completed a previous study. Participants will take ML-004 once daily, and researchers will monitor for side effects. The goal is to …
Phase: PHASE2 • Sponsor: MapLight Therapeutics • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC